<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096784</url>
  </required_header>
  <id_info>
    <org_study_id>ROPP-2008-01</org_study_id>
    <secondary_id>2007-007872-40</secondary_id>
    <nct_id>NCT01096784</nct_id>
  </id_info>
  <brief_title>IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity</brief_title>
  <official_title>Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the severity of retinopathy of prematurity (ROP) among treated infants with an
      untreated control population, matched for gestational age at birth while confirming the dose
      of rhIGF-1/rhIGFBP-3 is safe and efficacious.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When preterm infants are deprived of their natural intrauterine environment they lose access
      to important factors, normally found in utero, such as proteins, growth factors, and
      cytokines. It has been demonstrated that insulin-like growth factor-1 (IGF-1) is one such
      factor. In utero these biological factors are introduced to the fetus via placental
      absorption or ingestion from amniotic fluid. Deprivation of such factors is likely to cause
      inhibition or improper stimulation of important pathways, which in the case of the eye may
      cause abnormal retinal vascular growth, the hallmark of retinopathy of prematurity (ROP).

      Retinopathy of prematurity is the major cause of blindness in children in the developed and
      developing world, despite the availability of current treatment of late-stage ROP. As
      developing countries provide more neonatal and maternal intensive care, which increases the
      survival of preterm born infants, the incidence of ROP is increasing.

      This phase 2 study was originally designed in 3 sections, Sections A, B, and C which are now
      complete. The protocol was amended and patients enrolled from this point forward will be
      enrolled into Section D.

      In Study Section D, a total of 120 subjects (GA of 23 weeks + 0 days to 27 weeks + 6 days)
      will be randomly assigned with 1:1 allocation ratio to either treatment with
      rhIGF-1/rhIGFBP-3 or to receive standard neonatal care (Control Group) to obtain at least 80
      evaluable subjects. Duration of infusion will last at longest from Study Day 0 (day of birth)
      up to and including PMA 29 weeks + 6 days, when the subject's endogenous production of IGF-1
      is considered sufficient to maintain physiologic serum IGF-1 levels. After discontinuation of
      study drug infusion, each subject will be followed to PMA 40 weeks ± 4 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1, 2010</start_date>
  <completion_date type="Actual">March 1, 2016</completion_date>
  <primary_completion_date type="Actual">March 1, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of Retinopathy of Prematurity (ROP) as Compared to the Severity of ROP in an Untreated Control Population</measure>
    <time_frame>End of study</time_frame>
    <description>ROP was measured by central exams with fundus photography. Maximum severity of ROP stage across all retinal examinations included International Classification of Retinopathy of Prematurity, a 5 stage system, for the classification of ROP with 7 different outcomes of the ROP stage in each retinal examination: 0, 1, 2, 3, 3+, 4, and 5. This is an ordinal scale with higher numbers indicating a more severe outcome. The maximum severity of ROP across all time points was assessed from 31 PMA weeks up to 40 PMA Weeks +/- 4 days (end of study).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge From Neonatal Intensive Care (TDNIC)</measure>
    <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bronchopulmonary Dysplasia (BPD)</measure>
    <time_frame>At 36 Weeks Post Menstrual Age</time_frame>
    <description>Severity of BPD as mild, moderate and severe were based on the National Institute of Child Health and Human Development (NICHD) guidelines for preterm infants born at gestational age (GA) less than (&lt;) 32 weeks.
Mild: oxygen requirement during the first 28 days but in room air at PMA 36 weeks or discharge to home, whichever comes first.
Moderate BPD: oxygen requirement during the first 28 days and oxygen &lt;30 percent (%) at PMA 36 weeks or discharge to home, whichever comes first.
Severe BPD: oxygen requirement during the first 28 days and oxygen greater than equal (≥)30% through head hood or nasal canula, or continuous positive airway pressure, or mechanical ventilation, or high flow nasal cannula ≥2 L/min at PMA 36 weeks or discharge to home, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in Body Weight</measure>
    <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
    <description>The rate of change is the rate of specific body weight change per day in kilogram (kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in Length</measure>
    <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
    <description>The rate of change is the length change per day in centimeter (cm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in Head Circumference</measure>
    <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
    <description>The rate of change is the head circumference change per day in centimetre (cm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Development Assessed by Brain Volume at 40 Weeks PMA/EOS</measure>
    <time_frame>40 Weeks PMA/ (EOS) +/- 4 days</time_frame>
    <description>Brain volume was measured using cerebral magnetic resonance imaging (MRI). Brain volume included cerebrospinal volume, gray matter volume, white matter volume, and total cerebellar volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Intraventricular Hemorrhage (IVH)</measure>
    <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
    <description>Development of intraventricular hemorrhage was assessed by cerebral ultrasound and coded as a binary endpoint (presence or absence of IVH).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve for Maximum Severity of ROP Stage (AUC for ROP)</measure>
    <time_frame>Every 1-2 weeks starting at 31 weeks PMA/ EOS +/- 4 days</time_frame>
    <description>Integration of the maximum severity of ROP stage and the duration of the time interval with respect to each retinal examination. AUC for the maximum severity of ROP was calculated using the trapezoidal rule. The area between each 2 visits was calculated by multiplying the average of the maximum severities of the 2 visits by the difference in days and analyzed using the van Elteren test. ROP is classified according to the International Classification and is subdivided into 5 stages (1-5) with higher values representing greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Maximum Severity of ROP Stage Greater Than or Equal to 3 at Any Time During the Study</measure>
    <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
    <description>ROP was measured by central exams with fundus photography. Maximum severity of ROP stage across all retinal examinations included International Classification of Retinopathy of Prematurity, a 5 stage system, for the classification of ROP with 7 different outcomes of the ROP stage in each retinal examination: 0, 1, 2, 3, 3+, 4, and 5. This is an ordinal scale with higher numbers indicating a more severe outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE)</measure>
    <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent adverse event was defined as the onset of any AE or if the severity of a pre-existing AE worsened any time on or after the date of first dose of investigational product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Serum IGF-1 Concentrations Falling Within Target Range After Infusion of rhIGF-1/rhIGFBP-3</measure>
    <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
    <description>Serum samples were collected from treated and control participants for quantification of IGF-1 using validated immunoassays. Target range of serum IGF-1 was 28-109 mcg/L. The percentage of serum IGF-1 levels across treated participants that fall within the range was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of IGFBP-3 After Intravenous (IV) Infusion of rhIGF-1/rhIGFBP-3</measure>
    <time_frame>Day 0 and Week 40 Post Menstrual Age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Acid Labile Sub-unit (ALS) After Intravenous (IV) Infusion of rhIGF-1/rhIGFBP-3</measure>
    <time_frame>Day 7 and Week 40 Post Menstrual Age</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Retinopathy of Prematurity (ROP)</condition>
  <arm_group>
    <arm_group_label>rhIGF-I/rhIGFBP-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous IV Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The comparator group will receive no treatment with rhIGF-1/rhIGFBP-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhIGF-I/rhIGFBP-3</intervention_name>
    <description>Continuous intravenous infusion</description>
    <arm_group_label>rhIGF-I/rhIGFBP-3</arm_group_label>
    <other_name>Mecasermin Rinfabate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent from parents/guardians;

          -  Subject must be between GA of 26 weeks + 0 days and 27 weeks + 6 days (Study Section
             A) or between GA of 23 weeks + 0 days and 27 weeks + 6 days (Study Sections B, C, and
             D), inclusive

        Exclusion Criteria:

          -  Subjects born small for gestational age (SGA), ie, body weight at birth &lt;-2 standard
             deviation score (SDS) (Study Section A only)

          -  Detectable gross malformation

          -  Known or suspected chromosomal abnormality, genetic disorder, or syndrome, according
             to the Investigator's opinion

          -  Persistent blood glucose level &lt;2.5 mmol/L or &gt;10 mmol/L at Study Day 0 (day of birth)
             to exclude severe congenital abnormalities of glucose metabolism

          -  Anticipated need of administration of erythropoietin (rhEPO) during treatment with
             study drug.

          -  Any maternal diabetes requiring insulin during the pregnancy

          -  Clinically significant neurological disease according to the Investigator's
             opinion(Stage 1 IVH allowed)

          -  Any other condition or therapy that, in the Investigator's opinion, may pose a risk to
             the subject or interfere with the subject's ability to be compliant with this protocol
             or interfere with interpretation of results

          -  Monozygotic twins

          -  Subject participating or plans to participate in a clinical study of another
             investigational study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Day</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Mangili, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adina Tocoian, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama Children's and Women's Hospital</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604-3391</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California Irvine Med Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vidant Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>D.A.I. Materno Infantile, S.O.D. Neonatologia e Terapia Intensiva Neonatale - Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C Patologia e Terapia Intensiva Neonatale, Istituto Giannina Gaslini-Istituto Pediatrico di Ricovero e Cura a Carattere Scientifico</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padua</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento per la Tutella della Salute della Donna e della Vita Nascente, del Bambino e dell'Adolescente-U.O.C. Neonatologia-Poli. Gemelli</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki</name>
      <address>
        <city>Lódz</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ginekologiczno-Położniczy Szpital Kliniczny Uniwersytetu Medycznego w Poznani</name>
      <address>
        <city>Poznan</city>
        <zip>60-535</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universtitetssjukhuset i Huddinge</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Peter's Hospital; Ashford &amp; S</name>
      <address>
        <city>Chertsey</city>
        <zip>KT16 OPZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL EGA Institute for Women's Health</name>
      <address>
        <city>London</city>
        <zip>WC1E 6AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University</name>
      <address>
        <city>Norfolk</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Löfqvist C, Niklasson A, Engström E, Friberg LE, Camacho-Hübner C, Ley D, Borg J, Smith LE, Hellström A. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res. 2009 May;65(5):574-9. doi: 10.1203/PDR.0b013e31819d9e8c.</citation>
    <PMID>19190540</PMID>
  </reference>
  <results_reference>
    <citation>Ley D, Hansen-Pupp I, Niklasson A, Domellöf M, Friberg LE, Borg J, Löfqvist C, Hellgren G, Smith LE, Hård AL, Hellström A. Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety. Pediatr Res. 2013 Jan;73(1):68-74. doi: 10.1038/pr.2012.146. Epub 2012 Oct 24.</citation>
    <PMID>23095978</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2010</study_first_posted>
  <results_first_submitted>September 28, 2016</results_first_submitted>
  <results_first_submitted_qc>May 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2017</results_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin-like growth factor</keyword>
  <keyword>ROP</keyword>
  <keyword>IGF-I</keyword>
  <keyword>BPD</keyword>
  <keyword>bronchopulmonary dysplasia</keyword>
  <keyword>retinopathy of prematurity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in multiple centres in Italy, the Netherlands, Poland, Sweden, the United Kingdom and the United States between 18 Jun 2010 and 30 March 2016.</recruitment_details>
      <pre_assignment_details>A total of 121 participants were enrolled and randomized into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>rhIGF-1/rhIGFBP-3</title>
          <description>Participants received insulin-like growth factor (rhIGF-I)/insulin-like growth factor binding protein-3 (rhIGFBP-3) 250 microgram per kilogram (mcg/kg) for 24 hours through continuous intravenous (IV) infusion from Day 0 up to 29 weeks 6 days of post-menstrual age (PMA).</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care (Control)</title>
          <description>Participants in this control group do not received any treatment other than the standard care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat (ITT) set included all enrolled participants for whom a randomization number was assigned.</population>
      <group_list>
        <group group_id="B1">
          <title>rhIGF-1/rhIGFBP-3</title>
          <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care (Control)</title>
          <description>Participants in this control group do not received any treatment other than the standard care.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.60" spread="1.207"/>
                    <measurement group_id="B2" value="25.62" spread="1.397"/>
                    <measurement group_id="B3" value="25.61" spread="1.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severity of Retinopathy of Prematurity (ROP) as Compared to the Severity of ROP in an Untreated Control Population</title>
        <description>ROP was measured by central exams with fundus photography. Maximum severity of ROP stage across all retinal examinations included International Classification of Retinopathy of Prematurity, a 5 stage system, for the classification of ROP with 7 different outcomes of the ROP stage in each retinal examination: 0, 1, 2, 3, 3+, 4, and 5. This is an ordinal scale with higher numbers indicating a more severe outcome. The maximum severity of ROP across all time points was assessed from 31 PMA weeks up to 40 PMA Weeks +/- 4 days (end of study).</description>
        <time_frame>End of study</time_frame>
        <population>Full Analysis Set (FAS) included all randomized participants who received the study drug and participants in the control group who received Standard of Care.</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Retinopathy of Prematurity (ROP) as Compared to the Severity of ROP in an Untreated Control Population</title>
          <description>ROP was measured by central exams with fundus photography. Maximum severity of ROP stage across all retinal examinations included International Classification of Retinopathy of Prematurity, a 5 stage system, for the classification of ROP with 7 different outcomes of the ROP stage in each retinal examination: 0, 1, 2, 3, 3+, 4, and 5. This is an ordinal scale with higher numbers indicating a more severe outcome. The maximum severity of ROP across all time points was assessed from 31 PMA weeks up to 40 PMA Weeks +/- 4 days (end of study).</description>
          <population>Full Analysis Set (FAS) included all randomized participants who received the study drug and participants in the control group who received Standard of Care.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ROP of Stage &quot;0&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROP of Stage &quot;1&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROP of Stage &quot;2&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROP of Stage &quot;3&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROP of Stage &quot;3+&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROP of Stage &quot;4&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROP of Stage &quot;5&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0642</p_value>
            <method>CMH Row Mean Score Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discharge From Neonatal Intensive Care (TDNIC)</title>
        <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
        <population>FAS with number of participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discharge From Neonatal Intensive Care (TDNIC)</title>
          <population>FAS with number of participants evaluable for this outcome.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.00" lower_limit="69.00" upper_limit="96.00"/>
                    <measurement group_id="O2" value="74.00" lower_limit="69.00" upper_limit="93.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bronchopulmonary Dysplasia (BPD)</title>
        <description>Severity of BPD as mild, moderate and severe were based on the National Institute of Child Health and Human Development (NICHD) guidelines for preterm infants born at gestational age (GA) less than (&lt;) 32 weeks.
Mild: oxygen requirement during the first 28 days but in room air at PMA 36 weeks or discharge to home, whichever comes first.
Moderate BPD: oxygen requirement during the first 28 days and oxygen &lt;30 percent (%) at PMA 36 weeks or discharge to home, whichever comes first.
Severe BPD: oxygen requirement during the first 28 days and oxygen greater than equal (≥)30% through head hood or nasal canula, or continuous positive airway pressure, or mechanical ventilation, or high flow nasal cannula ≥2 L/min at PMA 36 weeks or discharge to home, whichever comes first.</description>
        <time_frame>At 36 Weeks Post Menstrual Age</time_frame>
        <population>FAS with participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bronchopulmonary Dysplasia (BPD)</title>
          <description>Severity of BPD as mild, moderate and severe were based on the National Institute of Child Health and Human Development (NICHD) guidelines for preterm infants born at gestational age (GA) less than (&lt;) 32 weeks.
Mild: oxygen requirement during the first 28 days but in room air at PMA 36 weeks or discharge to home, whichever comes first.
Moderate BPD: oxygen requirement during the first 28 days and oxygen &lt;30 percent (%) at PMA 36 weeks or discharge to home, whichever comes first.
Severe BPD: oxygen requirement during the first 28 days and oxygen greater than equal (≥)30% through head hood or nasal canula, or continuous positive airway pressure, or mechanical ventilation, or high flow nasal cannula ≥2 L/min at PMA 36 weeks or discharge to home, whichever comes first.</description>
          <population>FAS with participants evaluable for this outcome.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No BPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to determine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in Body Weight</title>
        <description>The rate of change is the rate of specific body weight change per day in kilogram (kg).</description>
        <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in Body Weight</title>
          <description>The rate of change is the rate of specific body weight change per day in kilogram (kg).</description>
          <population>FAS</population>
          <units>kilogram per day (kg/day)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" lower_limit="0.019" upper_limit="0.022"/>
                    <measurement group_id="O2" value="0.023" lower_limit="0.021" upper_limit="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in Length</title>
        <description>The rate of change is the length change per day in centimeter (cm).</description>
        <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in Length</title>
          <description>The rate of change is the length change per day in centimeter (cm).</description>
          <population>FAS</population>
          <units>centimeter per day (cm/day)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.141" lower_limit="0.0132" upper_limit="0.149"/>
                    <measurement group_id="O2" value="0.156" lower_limit="0.147" upper_limit="0.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in Head Circumference</title>
        <description>The rate of change is the head circumference change per day in centimetre (cm).</description>
        <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in Head Circumference</title>
          <description>The rate of change is the head circumference change per day in centimetre (cm).</description>
          <population>FAS</population>
          <units>cm/day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.115" lower_limit="0.109" upper_limit="0.121"/>
                    <measurement group_id="O2" value="0.119" lower_limit="0.113" upper_limit="0.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Development Assessed by Brain Volume at 40 Weeks PMA/EOS</title>
        <description>Brain volume was measured using cerebral magnetic resonance imaging (MRI). Brain volume included cerebrospinal volume, gray matter volume, white matter volume, and total cerebellar volume</description>
        <time_frame>40 Weeks PMA/ (EOS) +/- 4 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Development Assessed by Brain Volume at 40 Weeks PMA/EOS</title>
          <description>Brain volume was measured using cerebral magnetic resonance imaging (MRI). Brain volume included cerebrospinal volume, gray matter volume, white matter volume, and total cerebellar volume</description>
          <population>FAS</population>
          <units>cubic centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebrospinal Fluid Volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.94" spread="26.788"/>
                    <measurement group_id="O2" value="93.70" spread="25.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gray Matter Volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.34" spread="31.797"/>
                    <measurement group_id="O2" value="221.98" spread="33.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Matter Volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.23" spread="25.565"/>
                    <measurement group_id="O2" value="117.62" spread="24.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cerebellar Volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.27" spread="5.302"/>
                    <measurement group_id="O2" value="19.20" spread="4.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Intraventricular Hemorrhage (IVH)</title>
        <description>Development of intraventricular hemorrhage was assessed by cerebral ultrasound and coded as a binary endpoint (presence or absence of IVH).</description>
        <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Intraventricular Hemorrhage (IVH)</title>
          <description>Development of intraventricular hemorrhage was assessed by cerebral ultrasound and coded as a binary endpoint (presence or absence of IVH).</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.67"/>
                    <measurement group_id="O2" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.33"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Curve for Maximum Severity of ROP Stage (AUC for ROP)</title>
        <description>Integration of the maximum severity of ROP stage and the duration of the time interval with respect to each retinal examination. AUC for the maximum severity of ROP was calculated using the trapezoidal rule. The area between each 2 visits was calculated by multiplying the average of the maximum severities of the 2 visits by the difference in days and analyzed using the van Elteren test. ROP is classified according to the International Classification and is subdivided into 5 stages (1-5) with higher values representing greater severity.</description>
        <time_frame>Every 1-2 weeks starting at 31 weeks PMA/ EOS +/- 4 days</time_frame>
        <population>Full analysis set with number of participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve for Maximum Severity of ROP Stage (AUC for ROP)</title>
          <description>Integration of the maximum severity of ROP stage and the duration of the time interval with respect to each retinal examination. AUC for the maximum severity of ROP was calculated using the trapezoidal rule. The area between each 2 visits was calculated by multiplying the average of the maximum severities of the 2 visits by the difference in days and analyzed using the van Elteren test. ROP is classified according to the International Classification and is subdivided into 5 stages (1-5) with higher values representing greater severity.</description>
          <population>Full analysis set with number of participants evaluable for this outcome.</population>
          <units>ROP severity score*days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.95" spread="47.384"/>
                    <measurement group_id="O2" value="32.17" spread="40.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Maximum Severity of ROP Stage Greater Than or Equal to 3 at Any Time During the Study</title>
        <description>ROP was measured by central exams with fundus photography. Maximum severity of ROP stage across all retinal examinations included International Classification of Retinopathy of Prematurity, a 5 stage system, for the classification of ROP with 7 different outcomes of the ROP stage in each retinal examination: 0, 1, 2, 3, 3+, 4, and 5. This is an ordinal scale with higher numbers indicating a more severe outcome.</description>
        <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Maximum Severity of ROP Stage Greater Than or Equal to 3 at Any Time During the Study</title>
          <description>ROP was measured by central exams with fundus photography. Maximum severity of ROP stage across all retinal examinations included International Classification of Retinopathy of Prematurity, a 5 stage system, for the classification of ROP with 7 different outcomes of the ROP stage in each retinal examination: 0, 1, 2, 3, 3+, 4, and 5. This is an ordinal scale with higher numbers indicating a more severe outcome.</description>
          <population>FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.53"/>
                    <measurement group_id="O2" value="18.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.47"/>
                    <measurement group_id="O2" value="82.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent adverse event was defined as the onset of any AE or if the severity of a pre-existing AE worsened any time on or after the date of first dose of investigational product.</description>
        <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
        <population>Safety Analysis Set (SAF) included all randomized participants who received the study drug and participants in the control group who received standard of care, and for whom at least 1 safety assessment was completed.</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent adverse event was defined as the onset of any AE or if the severity of a pre-existing AE worsened any time on or after the date of first dose of investigational product.</description>
          <population>Safety Analysis Set (SAF) included all randomized participants who received the study drug and participants in the control group who received standard of care, and for whom at least 1 safety assessment was completed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Serum IGF-1 Concentrations Falling Within Target Range After Infusion of rhIGF-1/rhIGFBP-3</title>
        <description>Serum samples were collected from treated and control participants for quantification of IGF-1 using validated immunoassays. Target range of serum IGF-1 was 28-109 mcg/L. The percentage of serum IGF-1 levels across treated participants that fall within the range was reported.</description>
        <time_frame>Day 0 to 40 Weeks Post Menstrual Age (EOS)</time_frame>
        <population>FAS was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-I/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Serum IGF-1 Concentrations Falling Within Target Range After Infusion of rhIGF-1/rhIGFBP-3</title>
          <description>Serum samples were collected from treated and control participants for quantification of IGF-1 using validated immunoassays. Target range of serum IGF-1 was 28-109 mcg/L. The percentage of serum IGF-1 levels across treated participants that fall within the range was reported.</description>
          <population>FAS was analysed.</population>
          <units>percentage of serum concentration</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.23"/>
                    <measurement group_id="O2" value="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of IGFBP-3 After Intravenous (IV) Infusion of rhIGF-1/rhIGFBP-3</title>
        <time_frame>Day 0 and Week 40 Post Menstrual Age</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of IGFBP-3 After Intravenous (IV) Infusion of rhIGF-1/rhIGFBP-3</title>
          <population>FAS.</population>
          <units>microgram per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494.2" spread="200.38"/>
                    <measurement group_id="O2" value="469.9" spread="180.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="830.1" spread="200.17"/>
                    <measurement group_id="O2" value="882.1" spread="274.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of Acid Labile Sub-unit (ALS) After Intravenous (IV) Infusion of rhIGF-1/rhIGFBP-3</title>
        <time_frame>Day 7 and Week 40 Post Menstrual Age</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>rhIGF-1/rhIGFBP-3</title>
            <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (Control)</title>
            <description>Participants in this control group do not received any treatment other than the standard care.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Acid Labile Sub-unit (ALS) After Intravenous (IV) Infusion of rhIGF-1/rhIGFBP-3</title>
          <population>FAS.</population>
          <units>microgram per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411.9" spread="237.91"/>
                    <measurement group_id="O2" value="500.3" spread="350.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1804.6" spread="629.61"/>
                    <measurement group_id="O2" value="2114.3" spread="941.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 0 upto 4 days from PMA 40 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>rhIGF-I/rhIGFBP-3</title>
          <description>Participants received rhIGF-I/rhIGFBP-3 250 mcg/kg for 24 hours through continuous IV infusion from Day 0 up to 29 weeks 6 days of PMA.</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care (Control)</title>
          <description>Participants in this control group do not received any treatment other than the standard care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation disorder neonatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia neonatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="61"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinopathy of prematurity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intra-Abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Meconium ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Necrotising enterocolitis neonatal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Citrobacter sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Group b streptococcus neonatal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Serratia sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Pco2 increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperammonaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Convulsion neonatal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage neonatal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Periventricular leukomalacia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure neonatal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchopulmonary dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infantile apnoeic attack</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory failure</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary interstitial emphysema syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia neonatal</sub_title>
                <counts group_id="E1" events="210" subjects_affected="46" subjects_at_risk="61"/>
                <counts group_id="E2" events="157" subjects_affected="44" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Coagulation disorder neonatal</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia neonatal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia neonatal</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia neonatal</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal tachycardia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" events="67" subjects_affected="53" subjects_at_risk="61"/>
                <counts group_id="E2" events="57" subjects_affected="45" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinopathy of prematurity</sub_title>
                <counts group_id="E1" events="106" subjects_affected="39" subjects_at_risk="61"/>
                <counts group_id="E2" events="89" subjects_affected="37" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting neonatal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia neonatal</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal cholestasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" events="33" subjects_affected="16" subjects_at_risk="61"/>
                <counts group_id="E2" events="29" subjects_affected="15" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>C-Reactive protein increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Feeding disorder neonatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="24" subjects_at_risk="61"/>
                <counts group_id="E2" events="55" subjects_affected="28" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia neonatal</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="61"/>
                <counts group_id="E2" events="27" subjects_affected="19" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="14" subjects_at_risk="61"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="43" subjects_affected="17" subjects_at_risk="61"/>
                <counts group_id="E2" events="46" subjects_affected="22" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal hyponatraemia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="23" subjects_at_risk="61"/>
                <counts group_id="E2" events="39" subjects_affected="22" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Growth retardation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ventricle dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Convulsion neonatal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage neonatal</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="61"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Periventricular leukomalacia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" events="34" subjects_affected="28" subjects_at_risk="61"/>
                <counts group_id="E2" events="38" subjects_affected="30" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Poor weight gain neonatal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis neonatal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary dysplasia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="61"/>
                <counts group_id="E2" events="42" subjects_affected="37" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypocapnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infantile apnoeic attack</sub_title>
                <counts group_id="E1" events="42" subjects_affected="26" subjects_at_risk="61"/>
                <counts group_id="E2" events="32" subjects_affected="16" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal hypoxia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="61"/>
                <counts group_id="E2" events="21" subjects_affected="13" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory acidosis</sub_title>
                <counts group_id="E1" events="30" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="61"/>
                <counts group_id="E2" events="41" subjects_affected="32" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory failure</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neonatal tachypnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema neonatal</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal hypotension</sub_title>
                <counts group_id="E1" events="33" subjects_affected="23" subjects_at_risk="61"/>
                <counts group_id="E2" events="27" subjects_affected="15" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <email>ClinicalTransparency@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

